myCME Podcasts

Important: After listening to the podcast, you will need to visit myCME to complete the post-assessment and evaluation and to claim your credits and certificate for this activity. Please go to www.mycme.com/obesity3 on any browser to complete the activity. DescriptionPoorer health outcomes among individuals with overweight and obesity are made more likely and are being exacerbated by their experiencing weight-related stigma in healthcare settings, resulting in shorter office visits, less likelihood of preventive health screening, and fewer appropriate medical treatments.In this audio activity, Dr. Robert Kushner and Dr. Pamela Kushner review some of the potential biases that healthcare providers may unknowingly harbor related to obesity, and how these perceptions can negatively impact patient care. The faculty provide practical strategies that clinicians can implement to improve communication with their patients with obesity, and discuss methods for keeping patients engaged in obesity care over the long-term.This activity is designed for primary care providers (MDs/DOs, PAs, NPs), endocrinologists, cardiologists, dieticians/nutritionist, pharmacists, and other members of the multidisciplinary obesity care team.This activity is supported by an educational grant from Novo Nordisk.At the conclusion of this activity, participants should be better able to:Implement practical interventions to destigmatize obesity, surmount barriers to maintenance of weight loss over the long term, and enhance patient engagementFacultyPamela Kushner, MD, FAAFPClinical ProfessorUniversity of California at IrvineIrvine, CADr. Pamela Kushner is a consultant for Abbott, Intuity Medical, Inc., and Phathom Pharmaceuticals and is speaker and consultant for AstraZeneca, Eli Lilly and Company, GSK, and Janssen Pharmaceuticals, Inc.Robert F. Kushner, MD, MS, FACP, DABOMProfessor, Departments of Medicine and Medical EducationNorthwestern University Feinberg School of MedicineDirector, Center for Lifestyle Medicine, Northwestern MedicineChicago, ILDr. Robert Kushner is on the advisory board of Novo Nordisk and WW International, Inc., is a consultant for Pfizer Inc. and Altimmune, and has received research funding from Epitomee Medical.All of the relevant financial relationships listed for these individuals have been mitigated.

Important: After listening to the podcast, you will need to visit myCME to complete the post-assessment and evaluation and to claim your credits and certificate for this activity. Please go to www.mycme.com/obesity2 on any browser to complete the activity. DescriptionIn June 2021, the FDA approved a once-weekly, subcutaneous formulation of the GLP-1 receptor agonist semaglutide for chronic weight management in adults who are overweight or obese and have at least one weight-related comorbidity, making it the first new anti-obesity drug approved in the U.S. since 2014. While pharmacotherapy is an important tool for obesity management, these modalities must be appropriately used, based on the available evidence, established indications, and guidelines for therapeutic outcomes assessment.In this audio activity, Dr. Pamela Kushner and Dr. Ken Fujioka discuss appropriate obesity treatment goals individualized to the needs of each patient and review the reasons that patients frequently regain weight lost via lifestyle interventions. The faculty take a closer look at the spectrum of available pharmacologic options for obesity treatment and discuss how some of these agents directly target the pathophysiology that underlies the disease, resulting in meaningful weight loss.This activity is designed for primary care providers (MDs/DOs, PAs, NPs), endocrinologists, cardiologists, dieticians/nutritionist, pharmacists, and other members of the multidisciplinary obesity care team.This activity is supported by an educational grant from Novo Nordisk.At the conclusion of this activity, participants should be better able to:Describe the underlying pathophysiology of obesity and metabolic adaptations to weight lossApply the most recent evidence-based guidelines for the identification and individualized treatment of obesity in adults and other populationsReview efficacy, safety, and tolerability data for the full array of available and emerging pharmacotherapies to achieve and maintain clinically meaningful long-term weight lossFacultyPamela Kushner, MD, FAAFPClinical ProfessorUniversity of California at IrvineIrvine, CADr. Kushner is a consultant for Abbott, Intuity Medical, Inc., and Phathom Pharmaceuticals and is speaker and consultant for AstraZeneca, Eli Lilly and Company, GSK, and Janssen Pharmaceuticals, Inc.Ken Fujioka, MDDirector Nutrition and Metabolic ResearchScripps ClinicDivision of Diabetes and EndocrineSan Diego, CADr. Fujioka is a consultant for Novo Nordisk, Gelesis, Nalpropion Pharmaceuticals LLC, Amgen Inc., KVK Tech, Inc, Phenomix Sciences, LLC, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Rhythm Pharmaceuticals, Inc., and Takeda Pharmaceuticals. He is also on the speakers’ bureaus of Novo Nordisk, Nalpropion, Rhythm, and Takeda.All of the relevant financial relationships listed for these individuals have been mitigated.

Important: After listening to the podcast, you will need to visit myCME to complete the post-assessment and evaluation and to claim your credits and certificate for this activity. Please go to www.mycme.com/obesity1 on any browser to complete the activity. Despite widespread awareness of the potential long-term health consequences of obesity, this chronic disease is not often managed with the determination and urgency that it requires. Poor health outcomes among obese individuals are often exacerbated by weight-related stigma in healthcare settings, as well as lack of knowledge about the safety and efficacy of novel therapeutic options.This audio activity discusses the importance of early and sustained interventions for patients with obesity, as well as updated guidelines for identification and long-term management. The expert faculty review common obesity comorbidities as well as novel strategies to help patients overcome the metabolic adaptations that make it challenging to keep weight off with lifestyle interventions alone.This activity is designed for primary care providers (MDs/DOs, PAs, NPs), endocrinologists, cardiologists, dieticians/nutritionist, pharmacists, and other members of the multidisciplinary obesity care team.This activity is supported by an educational grant from Novo Nordisk.At the conclusion of this activity, participants should be better able to:Describe the underlying pathophysiology of obesity and metabolic adaptations to weight lossApply the most recent evidence-based guidelines for the identification and individualized treatment of obesity in adults and other populations FacultyDeepak L. Bhatt, MD, MPHExecutive Director of Interventional Cardiovascular ProgramsBrigham and Women’s Hospital Heart & Vascular CenterProfessor of MedicineHarvard Medical SchoolBoston, MADr. Bhatt has received researching funding from Abbott, Afimmune Limited, Amarin Pharma, Inc., Amgen Inc., AstraZeneca, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Cardax Inc., CellProthera, Cereno Scientific, Chiesi USA, Inc., CSL Behring LLC, Eisai, Inc., Eli Lilly and Company, Ethicon Inc., Faraday Pharmaceuticals, Ferring Pharmaceuticals Inc., Forest Laboratories Inc., Fractyl Health, Inc., Garmin International, Inc., HLS Therapeutics, Inc., Idorsia Pharmaceuticals Ltd., Ironwood Pharmaceuticals, Inc., Ischemix, Inc., Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Medtronic PLC, MyoKardia Inc., NirvaMed, Inc., Novartis Pharmaceuticals Corp., Novo Nordisk, Owkin, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, PLx Pharma Inc., Regeneron Pharmaceuticals, Inc., Roche Diagnostics Corp. (F. Hoffman-La Roche Ltd), Sanofi, Stasys Medical, Synaptic, The Medicines Company, and 89bio, Inc.Robert F. Kushner, MD, MS, FACP, DABOMProfessor, Departments of Medicine and Medical EducationNorthwestern University Feinberg School of MedicineDirector, Center for Lifestyle Medicine, Northwestern MedicineChicago, ILDr. Kushner is on the advisory board of Novo Nordisk and WW International, Inc., is a consultant for Pfizer Inc. and Altimmune, and has received research funding from Epitomee Medical.All of the relevant financial relationships listed for these individuals has been mitigated.

Important:  After listening to the podcast, you will need to visit myCME to complete the post-assessment and evaluation and to claim your credits and certificate for this activity. Please go to www.mycme.com/allergy1 on any browser to complete the activity.  Hypersensitivity reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are some of the most common drug reactions encountered in clinical practice. This program presents a practical approach to the evaluation and treatment of patients with NSAID allergies. This activity is designed for Allergists/Immunologists, as well as internists and primary care clinicians. This activity is not commercially supported. At the conclusion of this activity, participants should be better able to: Recognize and differentiate between the four common types of acute NSAID-induced reactionsDescribe the diagnostic evaluation for NSAID-induced reactionsAssess the safety of selective COX-2 inhibitors in patients reporting NSAID allergyDiscuss the role, safety, and efficacy of aspirin desensitization in patients with significant underlying pulmonary and cardiovascular diseaseExplain the current understanding of the mechanisms of NSAID-induced reactionsSpeaker Katherine Cahill, MDAssistant Professor of MedicineMedical Director of Clinical Asthma ResearchVanderbilt University Medical Center.Nashville, TN Dr. Cahill serves as an advisor for AstraZeneca, Blueprint Medicines Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline Pharmaceuticals Ltd, Novartis Pharmaceuticals Corp., and Sanofi. She is also a consultant for Ribon Therapeutics, Inc., Third Harmonic Bio, Inc., and Verantos, Inc. All of the relevant financial relationships listed for this individual have been mitigated.